Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021
Cancer Research and Treatment · 15.04.2024 · 56 (2) · 357-371
DOI: 10.4143/crt.2024.253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2024. Verfasst von Eun Hye Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: Korea Central Cancer Registry, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 181-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2021.Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2021, with survival follow-up until December 31, 2022. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
Results
The number of new cancer diagnoses in 2021 increased by 27,002 cases (10.8%) compared to 2020. In 2021, newly diagnosed cancer cases and deaths from cancer were reported as 277,523 (age-standardized rate [ASR], 289.3 per 100,000) and 82,688 (ASR, 67.6 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.3% from 2012 to 2015, thereafter, followed by non-significant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years (annual decrease of 2.8% from 2002 to 2013; 3.2% from 2013 to 2021). The 5-year relative survival between 2017 and 2021 was 72.1%, which contributed to prevalent cases reaching over 2.4 million in 2021.
Conclusion
In 2021, the number of newly diagnosed cancer patients increased as healthcare utilization recovered from the coronavirus disease 2019–related declines of 2020. Revised cancer registration guidelines expanded the registration scope, particularly for stomach and colorectal cancer. Survival rates have improved over the years, leading to a growing population of cancer survivors, necessitating a comprehensive cancer control strategy. The long-term impact of the pandemic on cancer statistics requires future investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Korea Central Cancer Registry, National Cancer Center, Goyang, Korea.
- Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea.
- National Cancer Control Institute, National Cancer Center, Goyang, Korea.
- National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Zitieren
APA
Park, E. H., Jung, K. W., Park, N. J., Kang, M. J., Yun, E. H., Kim, H. J., Kim, J. E., Kong, H. J., Im, J. S., Seo, H. G., & Community of Population-Based Regional Cancer Registries (2024). Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021. Cancer Research and Treatment, 56(2), 357-371. https://doi.org/10.4143/crt.2024.253
Vancouver
Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021. Cancer Research and Treatment. 2024;56(2):357-371. doi:10.4143/crt.2024.253
BibTeX
@article{Park2024,
author = {Park, Eun Hye and Jung, Kyu-Won and Park, Nam Ju and Kang, Mee Joo and Yun, E Hwa and Kim, Hye-Jin and Kim, Jeong-Eun and Kong, Hyun-Joo and Im, Jeong-Soo and Seo, Hong Gwan and Community of Population-Based Regional Cancer Registries, Community of Population-Based Regional Cancer Registries},
title = {Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021},
journal = {Cancer Research and Treatment},
year = {2024},
volume = {56},
number = {2},
pages = {357--371},
doi = {10.4143/crt.2024.253}
}
EUVIMED